Anti-Mouse CD200R [Clone OX-131] — Purified in vivo GOLD™ Functional Grade

Clone OX-131 does not appear in any authoritative list of monoclonal antibody clones for routine in vivo mouse research in the provided search results. No direct evidence is found detailing its molecular target, validated specificity, or characterized use in live mouse models.

Essential context and supporting details:

• None of the principal antibody databases or reagent suppliers included in the search (Bio X Cell, Bio-Rad, Creative Biolabs, Absolute Antibody) mention OX-131 among their panels of mouse-reactive antibodies used for in vivo functional, depleting, or blocking studies.
• Related clones such as OX-20 (anti-mouse kappa light chain), OX-97 (anti-mouse CD22), OX123 (anti-mouse SIRPB) are documented, but OX-131 is not referenced or described.
• The search results also include articles reviewing in vivo applications of various monoclonal antibodies in mice, discussions on tissue-seeking dyes, and platforms for conditional gene manipulation or base editing, but none mention OX-131 in any context related to mouse studies.

Additional relevant information:

• If clone OX-131 targets a mouse antigen, standard applications for monoclonals in vivo typically include:
  • Immune cell depletion (e.g., anti-CD4, anti-CD8)
  • Cell activation/blockade (activating/blocking receptor-ligand interactions)
  • Functional antagonism or agonism
  • Tumor/homing or tissue-specific targeting
• For any claim about OX-131’s in vivo function, it would be essential to provide specificity, published validation, and typical dosing or administration protocols. None are available in the search material.

Conclusion:There is no evidence available within the provided search results supporting any common in vivo applications of clone OX-131 in mice. If you seek information about a specific monoclonal antibody’s applications, confirming its target and referenced use in primary literature or validated reagent databases is essential. If you need data for another clone or clarification, please provide additional context, as possible numbers and clone designations may be easily confused.

Commonly used antibodies or proteins frequently paired with OX-131 in the literature include those targeting distinct but functionally related RSV F protein antigenic sites, such as antibodies specific to sites Ø, II, III, IV, and V, as well as anti-postfusion F protein antibodies like 131–2a. Additionally, multiplex experiments investigating RSV fusion protein use controls or comparators such as palivizumab (a monoclonal antibody targeting antigenic site II of RSV F), and often employ recombinant versions of F protein in either prefusion or postfusion conformation.

Key antibodies and proteins used with OX-131/research on RSV F protein:

• 131–2a: Widely used for detecting postfusion RSV F and specifically defines antigenic site I, often in combination with antibodies recognizing other sites (e.g., site II with palivizumab).
• Palivizumab: Recognizes RSV F protein at antigenic site II (distinct from site I), typically used as a benchmark or control in serological or structural analyses.
• Other site-specific mAbs: Panel antibodies recognizing antigenic sites Ø, II, III, IV, and V of RSV F are used to map the conformational landscape of the F protein, distinguishing prefusion and postfusion forms, and to compare the specificity of antibodies like OX-131.

Other approaches and reagents:

• Recombinant RSV F proteins in both prefusion and postfusion states serve as antigens for binding and epitope mapping.
• Secondary detection antibodies (e.g., anti-mouse or anti-human IgG HRP-conjugates) are standard in ELISA/Western blot protocols.
• Bispecific and engineered antibodies: In mechanistic or therapeutic studies, bispecific antibodies might combine RSV F specificity (e.g., targeting both F and another RSV surface protein or a T cell marker for retargeting).

In combination studies, OX-131 or functionally similar (postfusion-specific) antibodies are thus most often paired with:

• Site II (palivizumab)
• Other site-specific monoclonals (sites Ø, III, IV, V)
• Prefusion/postfusion F protein controls

This approach allows comprehensive mapping and functional characterization of immune responses to RSV F and comparison across conformational states.

Clone OX-131 appears to be a likely reference to the well-studied, multidrug-resistant Escherichia coli lineage known as ST131 (specifically, the O25b:H4 serotype), which is extensively cited in the scientific literature. The key findings from citations related to this clone are:

• Global Spread and Epidemiological Importance: E. coli ST131-O25b:H4 has been recognized as a globally dominant, multidrug-resistant clone responsible for a significant proportion of serious infections, particularly those resistant to extended-spectrum beta-lactamases (ESBLs).

• Association with Multidrug Resistance: This clone is most notable for its association with resistance to multiple antibiotics, including key β-lactams due to carriage of blaCTX-M-15 and other ESBL genes. The presence and propagation of IncF plasmids encoding these resistance genes are central to its success and evolutionary dominance.

• Clade Structure and Evolution: ST131 has distinct subclades—Clade A, B, and C—with Clade C (especially C2) being most associated with multidrug resistance and ESBL production. The clade’s evolution is characterized by both genetic diversification and, in clade C, evidence of a progressive loss of classical virulence genes which may paradoxically enhance persistence and spread.

• Molecular and Genomic Insights: Genome-wide studies have revealed that the core genomes of dominant subclades (C1 and C2) are highly conserved, but their accessory genomes are highly variable, allowing adaptation to different environments and selective pressures.

• Diagnostic Approaches: Molecular techniques such as fumC and fimH sequencing (CH clonotyping) and triplex PCRs have been developed to detect and differentiate ST131 and its subclones. These methods are now widely used for investigation and surveillance purposes.

• Key Citations in the Field: Seminal studies include:

  • Nicolas-Chanoine et al. (2008): First described the intercontinental emergence of E. coli O25:H4-ST131 producing CTX-M-15.
  • Johnson et al. (2010): Showed ST131 as the predominant cause of serious multidrug-resistant infections in the US.
  • Bonnin et al. (2012): Characterized IncFII plasmids encoding NDM-1 carbapenemase in ST131.
  • Olesen et al. (2013): Studied the prevalence and characteristics of ST131 in clinical samples.
  • Ongoing genomic surveys provide further insights into strain evolution and diversity.

In sum, ST131-O25b:H4 is widely cited as a key global driver of multidrug-resistant E. coli infections, with research focused on its epidemiology, resistance mechanisms, plasmid biology, evolution, and molecular detection methods.

There is no evidence in the provided search results that a mouse-specific antibody or drug called clone OX-131 exists. The search results extensively cover dosing regimens for several well-known antibodies and drugs in mouse models—such as RMP1-14, 10F.9G2, 29F.1A12, 9H10, 9D9 (all targeting PD-1, PD-L1, or CTLA-4), oxaliplatin, and radioiodine (I-131)—but none mention OX-131 as an experimental agent.

Clarification on “OX-131”

• The term OX-131 does not appear in the scientific literature included in the search.
• If you meant an anti-OX40 clone (e.g., OX-86), or a clone with a similar nomenclature, it is not present in the results.
• If “OX-131” was a typo or refers to a different compound (for example, Escherichia coli sequence type 131, which is unrelated to dosing regimens), please clarify.

How Dosing Regimens Vary Across Mouse Models

For widely used antibodies and drugs, dosing regimens can vary significantly depending on the target, mouse strain, model (e.g., tumor, infection, autoimmune), and experimental goals. Here are general principles based on the search results:

• Antibody Dosing: For checkpoint inhibitors like anti-PD-1, anti-PD-L1, and anti-CTLA-4, doses typically range from 100–500 μg per mouse, administered intraperitoneally every 2–4 days.
• Chemotherapy Agents: For oxaliplatin, a dose of 30 mg/kg was used in C57BL/6J mice to study neurotoxicity, with effects varying by sex and strain.
• Radioiodine Therapy: In I-131 studies, doses can range from 0.1 MBq to 23 MBq per mouse, with the choice depending on the experimental model (e.g., thyroid ablation, tumor targeting).
• Broad Variability: Dosing is often optimized in pilot studies, as strain, age, sex, and health status can all influence drug pharmacokinetics and pharmacodynamics.

Conclusion

Based on the provided search results, no information is available on the dosing regimen of “clone OX-131” in any mouse model. If you meant a different antibody or drug, please specify the correct name or target. If you are interested in dosing regimens for common antibodies or drugs in mouse models, the results provide detailed ranges and schedules for several well-characterized agents. For novel or less common clones, you may need to search the primary literature or contact the manufacturer/authors directly.